insights_auto
Por qué ha bajado 4142 6,62%?
Profundizarchevron_right
4142:TPE
Adimmune Corp
14,80 TWD
arrow_downward
-6,62%(-1,05) 1 d
20 nov, 13:30:09 GMT+8 · TWD
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de 4142...
Abrir
15,75 TWD
Alto
15,75 TWD
Bajo
14,80 TWD
Cap. burs.
6356,71 M
Vol. medio
1,13 M
Volumen
1,63 M
Ratio PER
85,76
Máximo en 52 sem.
21,50 TWD
Mínimo en 52 sem.
14,80 TWD
BPA
0,17 TWD
Acciones en circulación
235,29 M
N.º de empleados
564
Abrir
15,75 TWD
Alto
15,75 TWD
Bajo
14,80 TWD
Cap. burs.
6356,71 M
Vol. medio
1,13 M
Volumen
1,63 M
Ratio PER
85,76
Máximo en 52 sem.
21,50 TWD
Mínimo en 52 sem.
14,80 TWD
BPA
0,17 TWD
Acciones en circulación
235,29 M
N.º de empleados
564
Noticias
De fuentes web y partners de noticias
Bloomberg.com
·
hace 23 horas
Desplome tecnológico lleva al S&P 500 a corrección y golpea mercados globales
The Motley Fool
·
hace 1 hora
If the S&P 500 Drops by 20%, I'm Buying These 3 ETFs Without Hesitation
Yahoo Finance
·
hace 1 hora
Wall Street’s Fear Index Just Hit 9.7. History Says the S&P 500 Could Rally 10.5% in 3 Weeks
Trefis
·
hace 8 horas
S&P 500 Movers | Winners: GPN, GIS, MKC | Losers: BE, NVDA, LITE
Perfil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Acerca de Adimmune Corp